Peptides News and Research

RSS

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

Induced antibodies neutralize HIV-1; recognize peptides encapsulated in liposomes

For the first time, researchers have experimentally induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids. The results were reported by U.S. Military HIV Research Program (MHRP) researchers on Aug. 25 in the online version of AIDS, the official journal of the International AIDS Society.

2 Sep 2009

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

The American Diabetes Association Research Foundation has selected two scientists, University of Virginia Health System researcher Zhenqi Liu, MD, and Stanford University School of Medicine researcher Gerald Reaven, MD, to receive the American Diabetes Association-Novo Nordisk Clinical/Translational Research Award. This $1.2 million grant program supports efforts to study the effects of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease.

2 Sep 2009

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. Bile acid activation of the G protein-coupled receptor TGR5 has been shown to induce energy expenditure in muscle and brown fat, thereby conferring resistance to weight gain.

2 Sep 2009

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

1 Sep 2009

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

AVI BioPharma, Inc., a developer of RNA-based drugs, today announced that Hong Moulton, Ph.D., Director of Discovery Research, will give oral presentations highlighting improved analogues of AVI's phosphorodiamidate morpholino oligomer (PMO) chemistry at two upcoming scientific meetings.

28 Aug 2009

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.

27 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

New drug delivery system for delivering nanoparticles into the tissue

Scientists at UC Santa Barbara have discovered a potential new drug delivery system. The finding is a biological mechanism for delivery of nanoparticles into tissue. The results are published in this week's Proceedings of the National Academy of Sciences.

26 Aug 2009

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

Tripep and the German biotech company Cosmix AG have both licensed their respective technologies (RAS and mRNA Display Library) to a newly formed US company named Opsonic Therapeuticals Inc. within which Tripep’s RAS technology will be developed.

25 Aug 2009

RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

REGENERX BIOPHARMACEUTICALS, INC. (the “Company” or “RegeneRx”) announced today that it received a “Notice of Allowance” in Europe for its patent application: Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides.

25 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

CEL-SCI expands work on current H1N1 virus vaccine

CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.

19 Aug 2009

Research study highlights the biological importance of Vitamin D in humans and other primates

A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.

19 Aug 2009

Discovery of key factor that stimulates brain cancer cells to spread

Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). In a move toward therapy, the researchers showed that a small designer protein can block this activity and reduce the spreading of GBM cells grown in the laboratory.

19 Aug 2009

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting on September 2, 2009.

18 Aug 2009

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.

18 Aug 2009

Sigma-Aldrich offers customizable synthetic extracellular matrix (ECM) for stem cell research

Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement.

13 Aug 2009

Scientists grow new blood vessels to combat heart disease

Although open-heart surgery is a frequent treatment for heart disease, it remains extremely dangerous. Now groundbreaking research from Dr. Britta Hardy of Tel Aviv University's Sackler School of Medicine has shown the potential for an injected protein to regrow blood vessels in the human heart ― eliminating the need for risky surgery altogether.

13 Aug 2009

'Nanobee' drug delivery to tumors

When bees sting, they pump poison into their victims. Now the toxin in bee venom has been harnessed to kill tumor cells by researchers at Washington University School of Medicine in St. Louis. The researchers attached the major component of bee venom to nano-sized spheres that they call nanobees.

11 Aug 2009

Peptides News and Research

Hope for limiting skin toxicity of cancer drug users

Induced antibodies neutralize HIV-1; recognize peptides encapsulated in liposomes

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

New drug delivery system for delivering nanoparticles into the tissue

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

Nutra Pharma launches Cobroxin for chronic pain relief

CEL-SCI expands work on current H1N1 virus vaccine

Research study highlights the biological importance of Vitamin D in humans and other primates

Discovery of key factor that stimulates brain cancer cells to spread

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

Sigma-Aldrich offers customizable synthetic extracellular matrix (ECM) for stem cell research

Scientists grow new blood vessels to combat heart disease

'Nanobee' drug delivery to tumors

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News